Investigating the protective role of a cholesterol metabolite in diabetic kidney disease.
Official title: Protective role of CH25h/25-HC in diabetic kidney disease.
Funded at James J Peters VA Medical Center · NIH-11052023 · Data updated 2026-11-12
This study is looking at how a specific protein and its byproduct might impact kidney health in people with diabetic kidney disease, hoping to find new ways to help improve kidney function for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | James J Peters VA Medical Center NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01BX006837-01 |
| Project ID | NIH-11052023 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diabetic kidney disease.
✕Less likely to help
Patients without diabetes or those with advanced kidney disease may not benefit from this research.
What this research studies
This research focuses on understanding how cholesterol 25-hydroxylase (CH25H) and its product, 25-hydroxycholesterol (25-HC), affect kidney health in patients with diabetic kidney disease (DKD). By studying animal models that mimic early DKD, researchers aim to uncover the mechanisms by which CH25H influences endothelial cell function and inflammation in the kidneys. The goal is to clarify the role of CH25H in kidney pathology and potentially identify new therapeutic targets for improving kidney health in diabetic patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect kidney function in patients with diabetes.
How similar studies have gone: While the role of CH25H in kidney disease is not well-defined, preliminary data suggests that similar approaches have shown promise in understanding kidney pathology.
Where this research is happening
-
James J Peters VA Medical Center
Bronx, United States Active
Researchers
- Principal investigator: He, John Cijiang — James J Peters VA Medical Center
- Study coordinator: He, John Cijiang
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
LRG1’s role in diabetic kidney disease and kidney fibrosis
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Non-canonical NF-kB and inflammation in diabetic kidney disease
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
-
Epidermal microfluidic screen to detect diabetic kidney disease
A new skin-based microfluidic test platform may help identify kidney complications in people with diabetes using real-time biomarkers from sweat and glucose data.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.